References
- Hyrnuik W. M., Levine M. N., Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1986; 1: 87–94
- Bonadonna G., Valagussa P. Comment on “The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival”. Can Treat Rep 1983; 67: 527–529
- Hrynuik W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–1288
- Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985; 45: 4454–4459
- Komn A., Norton L., Perloff M., et al. Clinical equivalence despite dosage differences of the two schedules of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) for adjuvant therapy of node-positive stage II breast cancer. Proc Am Soc Clin Oncol 1988; 7: c–42
- Ragaz J., Ng V. Correlation of dose intensity (DI) of individual chemotherapy agents (CA) in the CMF combination with survival—review of a randomized adjuvant study. Proc Am Assoc Cancer Res 1988; 29: 788
- Perloff M., Norton L., Konun A., et al. Advantage of an adriamycin combination plus halotestin after initial CMFVP for adjuvant therapy of node-positive stage II breast cancer. Proc Am Soc Clin Oncol 1986; 5: c–273
- Hortobagyi G. N., Bodey G. P., Buzdar A. U., et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study. J Clin Oncol 1987; 5: 354–364
- Levine A. M., Richardson J. L., Chan K., et al. Level of compliance and effect of patient education on compliance with chemotherapy (Chemorx) among patients with hematologic malignancy. Proc Am Soc Clin Oncol 1984; 3: c–275
- Bull J. M., Tormey C. C., Lihou S., et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 1978; 41: 1649–1657